Vitiligo, New Treatment and Serum s100B
Condition(s) studied
Investigational drug(s) / intervention(s)
Baricitinib: oral baricitinib 4mg for adults and 2mg for children 10-16 years for group A
oral mini pulse: pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children
Narrow Band UVB Treatment: narrowband ultraviolet rays B phototherapy two sessions per week
Study summary
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem.
Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
Eligibility
Primary outcome measure(s)
- serum s100B in active generalized vitiligo — at the time of enrollment
detection of the relation of s100B to disease activity in comparison to control group, quantitative assessment of human s100B calcium-binding protein B (pg. /ml) using the available kit - the effect of treatments on s100B levels — after three months of the start of treatment
detection the effect of baricitinib ,oral mini-pulse and phototherapy on the serum levels of s100B by measuring the difference of s100B levels before and after three months of treatment . - clinical efficacy of oral baricitinib combined with phototherapy in stopping the progression of the disease. — from the enrollment to three to six months after the start of the treatment
-the ability of oral baricitinib combined with phototherapy in suppression the activity of the disease in comparison to the conventional treatment (oral mini pulse combined with phototherapy) will be measured using vitiligo diseases activity score (VIDA) in which +4 means highly active and 0 is stable - baricitinib combined with phototherapy in achieving satisfactory re-pigmentation. — from the enrollment to three to six months after the start of the treatment
the clinical efficacy of baricitinib +NB-UVB in achieving satisfactory re-pigmentation will be measured using vitiligo activity and severity index (VASI) scoring system in which more than or equal 75% represent excellent response and less than 25% is poor response
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Qena university hospital, Qena faculty of medicine | Qina | Egypt | Recruiting |
On this site
📄 Olumiant (baricitinib) drug profile →More South Valley University trials in Egypt
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06768840 on ClinicalTrials.gov ↗ ← All trials in Egypt